Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Saved in:
| Title: | Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. |
|---|---|
| Authors: | Roncolato FT; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia felicia.roncolato@ctc.usyd.edu.au.; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Macarthur Cancer Therapy Centre, New South Wales, Australia., Joly F; Centre Francois Baclesse, Caen, France., O'Connell R; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia., Lanceley A; University College London, London, England., Hilpert F; Klinik fur Gynakologie und Geburtshilfe, UKSH, Kiel, Germany., Buizen L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia., Okamoto A; The Jikei University School of Medicine, Tokyo, Japan., Aotani E; Kitasato Academic Research Organization, Tokyo, Japan., Pignata S; Istituto Nazionale per lo Studio e la Cura dei Tumori - Fondazione G. Pascale, IRCCS, Napoli (MITO), Italy., Donnellan P; Cancer Trials Ireland, Galway University Hospital, Galway, Ireland., Oza A; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Avall-Lundqvist E; Department of Oncology, Linköping University, Linköping, Sweden.; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.; Karolinska Institutet, Stockholm, Sweden., Berek JS; Stanford Comprehensive Cancer Institute, Stanford, California, USA., Heitz F; AGO Study group and Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany., Feeney A; Cancer Research UK & UCL Cancer Trials Centre, London, England., Berton-Rigaud D; ICO Centre René Gauducheau, Saint Herblain, France., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia., King M; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Psycho-oncology Research Group (PoCoG), School of Psychology and Sydney Medical School, University of Sydney, Sydney, Australia., Friedlander M; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Prince of Wales Hospital, Sydney, Australia. |
| Corporate Authors: | GCIG Symptom Benefit group |
| Source: | The oncologist [Oncologist] 2017 Sep; Vol. 22 (9), pp. 1117-1124. Date of Electronic Publication: 2017 Jun 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 28596446 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Roncolato+FT%22">Roncolato FT</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia felicia.roncolato@ctc.usyd.edu.au.; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Macarthur Cancer Therapy Centre, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Joly+F%22">Joly F</searchLink>; Centre Francois Baclesse, Caen, France.<br /><searchLink fieldCode="AU" term="%22O'Connell+R%22">O'Connell R</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Lanceley+A%22">Lanceley A</searchLink>; University College London, London, England.<br /><searchLink fieldCode="AU" term="%22Hilpert+F%22">Hilpert F</searchLink>; Klinik fur Gynakologie und Geburtshilfe, UKSH, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Buizen+L%22">Buizen L</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Okamoto+A%22">Okamoto A</searchLink>; The Jikei University School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Aotani+E%22">Aotani E</searchLink>; Kitasato Academic Research Organization, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Pignata+S%22">Pignata S</searchLink>; Istituto Nazionale per lo Studio e la Cura dei Tumori - Fondazione G. Pascale, IRCCS, Napoli (MITO), Italy.<br /><searchLink fieldCode="AU" term="%22Donnellan+P%22">Donnellan P</searchLink>; Cancer Trials Ireland, Galway University Hospital, Galway, Ireland.<br /><searchLink fieldCode="AU" term="%22Oza+A%22">Oza A</searchLink>; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Avall-Lundqvist+E%22">Avall-Lundqvist E</searchLink>; Department of Oncology, Linköping University, Linköping, Sweden.; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.; Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Berek+JS%22">Berek JS</searchLink>; Stanford Comprehensive Cancer Institute, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Heitz+F%22">Heitz F</searchLink>; AGO Study group and Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Feeney+A%22">Feeney A</searchLink>; Cancer Research UK & UCL Cancer Trials Centre, London, England.<br /><searchLink fieldCode="AU" term="%22Berton-Rigaud+D%22">Berton-Rigaud D</searchLink>; ICO Centre René Gauducheau, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Stockler+MR%22">Stockler MR</searchLink>; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22King+M%22">King M</searchLink>; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Psycho-oncology Research Group (PoCoG), School of Psychology and Sydney Medical School, University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Friedlander+M%22">Friedlander M</searchLink>; Australia New Zealand Gynaecological Oncology Group (ANZGOG), New South Wales, Australia.; Prince of Wales Hospital, Sydney, Australia. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22GCIG+Symptom+Benefit+group%22">GCIG Symptom Benefit group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2017 Sep; Vol. 22 (9), pp. 1117-1124. <i>Date of Electronic Publication: </i>2017 Jun 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28596446 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1634/theoncologist.2017-0047 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1117 Titles: – TitleFull: Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Roncolato FT – PersonEntity: Name: NameFull: Joly F – PersonEntity: Name: NameFull: O'Connell R – PersonEntity: Name: NameFull: Lanceley A – PersonEntity: Name: NameFull: Hilpert F – PersonEntity: Name: NameFull: Buizen L – PersonEntity: Name: NameFull: Okamoto A – PersonEntity: Name: NameFull: Aotani E – PersonEntity: Name: NameFull: Pignata S – PersonEntity: Name: NameFull: Donnellan P – PersonEntity: Name: NameFull: Oza A – PersonEntity: Name: NameFull: Avall-Lundqvist E – PersonEntity: Name: NameFull: Berek JS – PersonEntity: Name: NameFull: Heitz F – PersonEntity: Name: NameFull: Feeney A – PersonEntity: Name: NameFull: Berton-Rigaud D – PersonEntity: Name: NameFull: Stockler MR – PersonEntity: Name: NameFull: King M – PersonEntity: Name: NameFull: Friedlander M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2017 Sep Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 22 – Type: issue Value: 9 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |